表紙
市場調査レポート

薬剤溶出ステント:世界のパイプライン分析、競合環境、2017年までの市場予測

Drug Eluting Stents - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

発行 GlobalData 商品コード 208366
出版日 ページ情報 英文 185 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
薬剤溶出ステント:世界のパイプライン分析、競合環境、2017年までの市場予測 Drug Eluting Stents - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
出版日: 2011年08月05日 ページ情報: 英文 185 Pages
概要

世界の薬剤溶出ステント(DES)市場は2010年に46億米ドル規模となりました。同市場は2003年に16億9,000万米ドルとなって以来、CAGR15.4%で成長を続けてきました。今後は販売価格の低下により停滞する見込みです。

当レポートでは、世界の薬剤溶出ステント(DES)市場について調査分析し、冠動脈性心疾患の概要、DESの危険因子、市場収益実績、国別動向、参入企業の戦略的プロファイル、上市済み製品の概要などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要:冠動脈性心疾患(CHD)

  • 病因
  • 危険因子
  • 徴候と症状
  • 診断
    • 心電図
    • 心エコー
    • 血液検査
    • 冠動脈造影
    • 放射性核種件sあ
    • MRI
  • 疫学
    • 米国
    • 英国

第4章 装置の概要:薬剤溶出ステント(DES)

  • 危険因子

第5章 市場特性

  • 収益実績:2003〜2010年
  • 収益予測:2010〜2017年
  • 売上台数実績:2003〜2010年
  • 売上台数予測:2010〜2017年
  • 市場動向

第6章 国別分析:2003〜2017年

  • 米国
  • カナダ
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ブラジル

第7章 戦略的競合評価

  • 主要企業プロファイル
    • Boston Scientific
    • Abbott Laboratories
    • Medtronic Inc
    • Cordis Corporation

第8章 上市製品

第9章 戦略的パイプライン評価

  • バイオアブソーバブル薬剤溶出ステント
  • 開発段階別パイプライン評価
  • 臨床開発中の有望製品プロファイル

第10章 取引環境

  • 概要
  • 主な取引:2009〜2010年
    • Biosensors International GroupがDevaxから資産を買収
    • XenogenicsがIdeal BioStentの資産を買収
    • Biosensors InternationalがCardioMindを買収
    • Boston ScientificがLabcoatを買収
    • Svelte Medical SystemsがCordisとライセンス契約を締結

第11章 付録

目次
Product Code: GDME0079MAR

Summary

GlobalData’s new report, “Drug Eluting Stents - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017” provides key data, information and analysis on the global drug eluting stents market. The report provides market landscape, competitive landscape and market trends information on the drug eluting stents market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

• Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
• Annualized market revenues data from 2003 to 2010, forecast forward for 7 years to 2017. Company shares data for 2010.
• Qualitative analysis of key market trends, market drivers, and restraints for drug eluting stents market.
• The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
• Key players covered include Abbott Laboratories, Boston Scientific, Cordis Corporation and Medtronic.

Reasons To Buy

• Develop business strategies by understanding the trends and developments that are driving the drug eluting stents market globally.
• Design and develop your product development, marketing and sales strategies.
• Develop market-entry and market expansion strategies.
• Identify key players best positioned to take advantage of the emerging market opportunities.
• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
• What’s the next big thing in the drug eluting stents market landscape? - Identify, understand and capitalize.
• Make more informed business decisions from the insightful and in-depth analysis of the global drug eluting stents market and the factors shaping it.

Companies Mentioned

  • Boston Scientific
  • Abbott Laboratories
  • Medtronic Inc.
  • Cordis Corporation

Table of Contents

1. Table of contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. GlobalData Report Guidance

3. Disease Overview - Coronary Heart Disease (CHD)

  • 3.1. Etiology
  • 3.2. Risk Factors
  • 3.3. Signs and Symptoms
  • 3.4. Diagnosis
    • 3.4.1. Electrocardiogram (ECG)
    • 3.4.2. Echocardiogram
    • 3.4.3. Blood Tests
    • 3.4.4. Coronary Angiography
    • 3.4.5. Radionuclide tests
    • 3.4.6. Magnetic Resonance Imaging (MRI)
  • 3.5. Epidemiology
    • 3.5.1. Prevalence of CHD in the US
    • 3.5.2. Prevalence of CHD in the UK

4. Device Overview - Drug Eluting Stents (DES)

  • 4.1. Drug Eluting Stents: Risk Factors
    • 4.1.1. Stent Thrombosis (ST)

5. Drug Eluting Stents - Market Characterization

  • 5.1. Drug Eluting Stents Market, Global, Revenue ($m), Historic, 2003-2010
  • 5.2. Drug Eluting Stents Market, Global, Revenue ($m), Forecast, 2010-2017
  • 5.3. Drug Eluting Stents Market, Global, Volume (‘000), Historic, 2003-2010
  • 5.4. Drug Eluting Stents Market, Global, Volume (‘000), Forecast, 2010-2017
  • 5.5. Drug Eluting Stents, Market Dynamics
    • 5.5.1. Market Drivers
    • 5.5.2. Market Restraints

6. Drug Eluting Stents (DES) Market, Analysis by Country, Revenue ($m), 2003-2017

  • 6.1. Drug Eluting Stents Market, the US, Revenue ($bn), Historic, 2003-2010
  • 6.2. Drug Eluting Stents Market, the US, Volume (million), Historic, 2003-2010
  • 6.3. Drug Eluting Stents Market, the US, Revenue ($bn), Forecast, 2010-2017
  • 6.4. Drug Eluting Stents Market, the US, Volume (million), Forecast, 2010-2017
  • 6.5. Drug Eluting Stents Market, Canada, Revenue ($m), Historic, 2003-2010
  • 6.6. Drug Eluting Stents Market, Canada, Volume (‘000), Historic, 2003-2010
  • 6.7. Drug Eluting Stents Market, Canada, Revenue ($m), Forecast, 2010-2017
  • 6.8. Drug Eluting Stents Market, Canada, Volume (‘000), Forecast, 2010-2017
  • 6.9. Drug Eluting Stents Market, the UK, Revenue ($m), Historic, 2003-2010
  • 6.10. Drug Eluting Stents Market, the UK, Volume (‘000), Historic, 2003-2010
  • 6.11. Drug Eluting Stents Market, the UK, Revenue ($m), Forecast, 2010-2017
  • 6.12. Drug Eluting Stents Market, the UK, Volume (‘000), Forecast, 2010-2017
  • 6.13. Drug Eluting Stents Market, Germany, Revenue ($m), Historic, 2003-2010
  • 6.14. Drug Eluting Stents Market, Germany, Volume (‘000), Historic, 2003-2010
  • 6.15. Drug Eluting Stents Market, Germany, Revenue ($m), Forecast, 2010-2017
  • 6.16. Drug Eluting Stents Market, Germany, Volume (‘000), Forecast, 2010-2017
  • 6.17. Drug Eluting Stents Market, France, Revenue ($m), Historic, 2003-2010
  • 6.18. Drug Eluting Stents Market, France, Volume (‘000), Historic, 2003-2010
  • 6.19. Drug Eluting Stents Market, France, Revenue ($m), Forecast, 2010-2017
  • 6.20. Drug Eluting Stents Market, France, Volume (‘000), Forecast, 2010-2017
  • 6.21. Drug Eluting Stents Market, Italy, Revenue ($m), Historic, 2003-2010
  • 6.22. Drug Eluting Stents Market, Italy, Volume (‘000), Historic, 2003-2010
  • 6.23. Drug Eluting Stents Market, Italy, Revenue ($m), Forecast, 2010-2017
  • 6.24. Drug Eluting Stents Market, Italy, Volume (‘000), Forecast, 2010-2017
  • 6.25. Drug Eluting Stents Market, Spain, Revenue ($m), Historic, 2003-2010
  • 6.26. Drug Eluting Stents Market, Spain, Volume (‘000), Historic, 2003-2010
  • 6.27. Drug Eluting Stents Market, Spain, Revenue ($m), Forecast, 2010-2017
  • 6.28. Drug Eluting Stents Market, Spain, Volume (‘000), Forecast, 2010-2017
  • 6.29. Drug Eluting Stents Market, Japan, Revenue ($m), Historic, 2003-2010
  • 6.30. Drug Eluting Stents Market, Japan, Volume (‘000), Historic, 2003-2010
  • 6.31. Drug Eluting Stents Market, Japan, Revenue ($m), Forecast, 2010-2017
  • 6.32. Drug Eluting Stents Market, Japan, Volume (‘000), Forecast, 2010-2017
  • 6.33. Drug Eluting Stents Market, China, Revenue ($m), Historic, 2003-2010
  • 6.34. Drug Eluting Stents Market, China, Volume (‘000), Historic, 2003-2010
  • 6.35. Drug Eluting Stents Market, China, Revenue ($m), Forecast, 2010-2017
  • 6.36. Drug Eluting Stents Market, China, Volume (‘000), Forecast, 2010-2017
  • 6.37. Drug Eluting Stents Market, India, Revenue ($m), Historic, 2003-2010
  • 6.38. Drug Eluting Stents Market, India, Volume (‘000), Historic, 2003-2010
  • 6.39. Drug Eluting Stents Market, India, Revenue ($m), Forecast, 2010-2017
  • 6.40. Drug Eluting Stents Market, India, Volume (‘000), Forecast, 2010-2017
  • 6.41. Drug Eluting Stents Market, Australia, Revenue ($m), Historic, 2003-2010
  • 6.42. Drug Eluting Stents Market, Australia, Volume (‘000), Historic, 2003-2010
  • 6.43. Drug Eluting Stents Market, Australia, Revenue ($m), Forecast, 2010-2017
  • 6.44. Drug Eluting Stents Market, Australia, Volume (‘000), Forecast, 2010-2017
  • 6.45. Drug Eluting Stents Market, Brazil, Revenue ($m), Historic, 2003-2010
  • 6.46. Drug Eluting Stents Market, Brazil, Volume (‘000), Historic, 2003-2010
  • 6.47. Drug Eluting Stents Market, Brazil, Revenue ($m), Forecast, 2010-2017
  • 6.48. Drug Eluting Stents Market, Brazil, Volume (‘000), Forecast, 2010-2017

7. Drug Eluting Stents Market - Strategic Competitive Assessment

  • 7.1. Drug Eluting Stents Market: Key Player Profiles
  • 7.1.1. Boston Scientific
  • 7.1.2. Abbott Laboratories
  • 7.1.3. Medtronic Inc.
  • 7.1.4. Cordis Corporation

8. Drug Eluting Stents - Key Marketed Products

  • 8.1. TAXUS Liberté Paclitaxel-Eluting Coronary Stent System
    • 8.1.1. Product Description
    • 8.1.2. Features and Benefits
  • 8.2. PROMUS Everolimus-Eluting Coronary Stent System
    • 8.2.1. Product Description
    • 8.2.2. Features and Benefits
  • 8.3. XIENCE V Everolimus-Eluting Coronary Stent System
    • 8.3.1. Product Description
    • 8.3.2. Features and Benefits
  • 8.4. CYPHER Sirolimus-Eluting Coronary Stent
    • 8.4.1. Product Description
    • 8.4.2. Features and Benefits
  • 8.5. Endeavor Zotarolimus-Eluting Stent System
    • 8.5.1. Product Description
    • 8.5.2. Features and Benefits

9. Drug Eluting Stents Market - Strategic Pipeline Assessment

  • 9.1. Bioabsorbable Drug-eluting Stents
    • 9.1.1. Key Pipeline Products
  • 9.2. Drug Eluting Stents, Pipeline Assessment, by Development Stage
  • 9.3. Profiles of Promising Products under Clinical Development
    • 9.3.1. TAXUS Element (ION) Paclitaxel-Eluting Coronary Stent System
    • 9.3.2. XIENCE PRIME Everolimus-Eluting Coronary Stent System
    • 9.3.3. JACTAX Drug-eluting Stent
    • 9.3.4. PROMUS Element Everolimus-Eluting Coronary Stent
    • 9.3.5. Synergy Coronary Stent
    • 9.3.6. AVJ-09-385
    • 9.3.7. ZoMaxx Drug Eluting Coronary Stent System
    • 9.3.8. NEVO Sirolimus-Eluting Coronary Stent
    • 9.3.9. Endeavor Resolute

10. Drug Eluting Stents Market - Deals Landscape

  • 10.1. Drug Eluting Stents Marke - Deals Overview
  • 10.2. Key Deals (2009-2010)
    • 10.2.1. Biosensors International Group Acquired Assets from Devax
    • 10.2.2. Xenogenics Acquired Assets of Ideal BioStent
    • 10.2.3. Biosensors International acquires CardioMind
    • 10.2.4. Boston Scientific acquires Labcoat
    • 10.2.5. Svelte Medical Systems enters into Licensing Agreement with Cordis

11. Appendix

  • 11.1. Definitions
    • 11.1.1. Drug Eluting Stent (DES)
  • 11.2. Abbreviations (in alphabetical order)
  • 11.3. Research Methodology
    • 11.3.1. Secondary Research
    • 11.3.2. Primary Research
    • 11.3.3. Models
    • 11.3.4. Forecasts
    • 11.3.5. Expert Panel
  • 11.4. GlobalData Consulting
  • 11.5. Contact Us
  • 11.6. Disclaimer
  • 11.7. Sources

List of Tables

  • Table 1: Drug Eluting Stents, Classified by Drug Used, 2010
  • Table 2: Drug Eluting Stents Market, Global, Revenue ($m), 2003-2010
  • Table 3: Drug Eluting Stents Market, Global, Revenue ($m), 2010-2017
  • Table 4: Drug Eluting Stents Market, Global, Volume (‘000), 2003-2010
  • Table 5: Drug Eluting Stents Market, Global, Volume (‘000), 2010-2017
  • Table 6: Coronary Heart Disease, the US, Prevalence (%), 2010-2030
  • Table 7: Coronary Heart Disease in Men by Age, the UK, Prevalence (%), 2000-2008
  • Table 8: Coronary Heart Disease in Women by Age, the UK, Prevalence (%), 2000-2008
  • Table 9: Population Aged 65 and Above, Global, Population (million), 2004-2010
  • Table 10: Population Aged 60 and Above, the US, Population (million) and Population Aged 60 and Above as a Percentage (%) of Adult Population, 2000-2050
  • Table 11: Prevalence of Coronary Heart Disease in Population Aged between 60-79 and Population Aged 80 and Above, the US, Prevalence (%), 2006
  • Table 12: Population Aged 65 and above, the UK, Population (million) and Population Aged 65 and Above as a Percentage (%) of Adult Population, 2000-2050
  • Table 13: Coronary Heart Disease in Men Aged 65 and Above, the UK, Prevalence (%), 2000-2008
  • Table 14: Coronary Heart Disease in Women Aged 65 and Above, the UK, Prevalence (%), 2000-2008
  • Table 15: Tobacco Consumption, Global, Population (billion), 2000-2050
  • Table 16: Diabetes Prevalence, by Country, Prevalence (%), Latest Data Available
  • Table 17: Percutaneous Coronary Intervention Procedure (million), Global, 2003-2010
  • Table 18: Percutaneous Coronary Intervention Procedure (million), the US, 2003-2010
  • Table 19: Percutaneous Coronary Intervention Procedure (‘000), Europe, 2003-2010
  • Table 20: Drug Eluting Stents Market, by Country, Average Selling Price ($), 2003-2010
  • Table 21: Drug Eluting Stents Market, the US, Revenue ($bn), 2003-2010
  • Table 22: Drug Eluting Stents Market, the US, Volume (million), 2003-2010
  • Table 23: Drug Eluting Stents Market, the US, Revenue ($bn), 2010-2017
  • Table 24: Drug Eluting Stents Market, the US, Volume (million), 2010-2017
  • Table 25: Drug Eluting Stents Market, Canada, Revenue ($m), 2003-2010
  • Table 26: Drug Eluting Stents Market, Canada, Volume (‘000), 2003-2010
  • Table 27: Drug Eluting Stents Market, Canada, Revenue ($m), 2010-2017
  • Table 28: Drug Eluting Stents Market, Canada, Volume (‘000), 2010-2017
  • Table 29: Drug Eluting Stents Market, the UK, Revenue ($m), 2003-2010
  • Table 30: Drug Eluting Stents Market, the UK, Volume (‘000), 2003-2010
  • Table 31: Drug Eluting Stents Market, the UK, Revenue ($m), 2010-2017
  • Table 32: Drug Eluting Stents Market, the UK, Volume (‘000), 2010-2017
  • Table 33: Drug Eluting Stents Market, Germany, Revenue ($m), 2003-2010
  • Table 34: Drug Eluting Stents Market, Germany, Volume (‘000), 2003-2010
  • Table 35: Drug Eluting Stents Market, Germany, Revenue ($m), 2010-2017
  • Table 36: Drug Eluting Stents Market, Germany, Volume (‘000), 2010-2017
  • Table 37: Drug Eluting Stents Market, France, Revenue ($m), 2003-2010
  • Table 38: Drug Eluting Stents Market, France, Volume (‘000), 2003-2010
  • Table 39: Drug Eluting Stents Market, France, Revenue ($m), 2010-2017
  • Table 40: Drug Eluting Stents Market, France, Volume (‘000), 2010-2017
  • Table 41: Drug Eluting Stents Market, Italy, Revenue ($m), 2003-2010
  • Table 42: Drug Eluting Stents Market, Italy, Volume (‘000), 2003-2010
  • Table 43: Drug Eluting Stents Market, Italy, Revenue ($m), 2010-2017
  • Table 44: Drug Eluting Stents Market, Italy, Volume (‘000), 2010-2017
  • Table 45: Drug Eluting Stents Market, Spain, Revenue ($m), 2003-2010
  • Table 46: Drug Eluting Stents Market, Spain, Volume (‘000), 2003-2010
  • Table 47: Drug Eluting Stents Market, Spain, Revenue ($m), 2010-2017
  • Table 48: Drug Eluting Stents Market, Spain, Volume (‘000), 2010-2017
  • Table 49: Drug Eluting Stents Market, Japan, Revenue ($m), 2003-2010
  • Table 50: Drug Eluting Stents Market, Japan, Volume (‘000), 2003-2010
  • Table 51: Drug Eluting Stents Market, Japan, Revenue ($m), 2010-2017
  • Table 52: Drug Eluting Stents Market, Japan, Volume (‘000), 2010-2017
  • Table 53: Drug Eluting Stents Market, China, Revenue ($m), 2003-2010
  • Table 54: Drug Eluting Stents Market, China, Volume (‘000), 2003-2010
  • Table 55: Drug Eluting Stents Market, China, Revenue ($m), 2010-2017
  • Table 56: Drug Eluting Stents Market, China, Volume (‘000), 2010-2017
  • Table 57: Drug Eluting Stents Market, India, Revenue ($m), 2003-2010
  • Table 58: Drug Eluting Stents Market, India, Volume (‘000), 2003-2010
  • Table 59: Drug Eluting Stents Market, India, Revenue ($m), 2010-2017
  • Table 60: Drug Eluting Stents Market, India, Volume (‘000), 2010-2017
  • Table 61: Drug Eluting Stents Market, Australia, Revenue ($m), 2003-2010
  • Table 62: Drug Eluting Stents Market, Australia, Volume (‘000), 2003-2010
  • Table 63: Drug Eluting Stents Market, Australia, Revenue ($m), 2010-2017
  • Table 64: Drug Eluting Stents Market, Australia, Volume (‘000), 2010-2017
  • Table 65: Drug Eluting Stents Market, Brazil, Revenue ($m), 2003-2010
  • Table 66: Drug Eluting Stents Market, Brazil, Volume (‘000), 2003-2010
  • Table 67: Drug Eluting Stents Market, Brazil, Revenue ($m), 2010-2017
  • Table 68: Drug Eluting Stents Market, Brazil, Volume (‘000), 2010-2017
  • Table 69: Drug Eluting Stents Market, Global, Company Share ($m), 2010
  • Table 70: Boston Scientific Marketed Products, 2011
  • Table 71: Boston Scientific Pipeline Products, 2011
  • Table 72: Abbott Laboratories Marketed Products, 2011
  • Table 73: Abbott Laboratories Pipeline Products, 2011
  • Table 74: Medtronic Inc. Marketed Products, 2011
  • Table 75: Medtronic Inc. Pipeline Products, 2011
  • Table 76: Cordis Corporation Marketed Products, 2011
  • Table 77: Cordis Corporation Pipeline Products, 2011
  • Table 78: Absorb Product Status
  • Table 79: Absorb Clinical Trial 1
  • Table 80: Absorb Clinical Trial 2
  • Table 81: Absorb Clinical Trial 3
  • Table 82: Bioresorbable Stent Product Status
  • Table 83: Biosorb Product Status
  • Table 84: Drug Eluting Absorbable Metal Scaffold Product Status
  • Table 85: Drug Eluting Absorbable Metal Scaffold Clinical Trials
  • Table 86: Fully Biodegradable Stent Product Status
  • Table 87: IDEAL Stent Product Status
  • Table 88: Myolimus-Eluting Coronary Stent - Bioabsorbable Polymer Product Status
  • Table 89: Myolimus-Eluting Coronary Stent - Bioabsorbable Polymer Clinical Trials
  • Table 90: Peptide-Eluting Coronary Stent Product Status
  • Table 91: RESORB Product Status
  • Table 92: ReZolve Bioresorbable Coronary Stent Product Status
  • Table 93: ReZolve Bioresorbable Coronary Stent Clinical Trials
  • Table 94: TephaFLEX Absorbable Stent Product Status
  • Table 95: Whisper Coronary Stent System Product Status
  • Table 96: Whisper Coronary Stent System Clinical Trials
  • Table 97: Product Status
  • Table 98: TAXUS Element Clinical Trial 1
  • Table 99: TAXUS Element Clinical Trial 2
  • Table 100: TAXUS Element Clinical Trial 3
  • Table 101: Product Status
  • Table 102: XIENCE PRIME Clinical Trial 1
  • Table 103: DARE Trial
  • Table 104: XIENCE PRIME Clinical Trial 3
  • Table 105: XIENCE PRIME Clinical Trial 4
  • Table 106: XIENCE PRIME Clinical Trial 5
  • Table 107: Product Status
  • Table 108: JACTAX Clinical Trial 1
  • Table 109: JACTAX Clinical Trial 2
  • Table 110: JACTAX Clinical Trial 3
  • Table 111: Product Status
  • Table 112: PROMUS Clinical Trial 1
  • Table 113: PROMUS Clinical Trial 2
  • Table 114: PROMUS Clinical Trial 3
  • Table 115: PROMUS Clinical Trial 4 (EVOLVE)
  • Table 116: PROMUS Clinical Trail 5
  • Table 117: PROMUS Clinical Trial 6
  • Table 118: Product Status
  • Table 119: Synergy Clinical Trial (EVOLVE)
  • Table 120: Product Status
  • Table 121: AVJ-09-385 Clinical Trial
  • Table 122: Product Status
  • Table 123: ZoMaxx Clinical Trial
  • Table 124: Product Status
  • Table 125: NEVO Clinical Trial 1
  • Table 126: NEVO Clinical Trial 2
  • Table 127: NEVO Clinical Trial 3
  • Table 128: NEVO Clinical Trial 4
  • Table 129: NEVO Clinical Trial 5
  • Table 130: NEVO Clinical Trial 6
  • Table 131: Product Status
  • Table 132: Endeavor Resolute Clinical Trial 1
  • Table 133: Endeavor Resolute Clinical Trial 2
  • Table 134: Endeavor Resolute Clinical Trial 3
  • Table 135: Endeavor Resolute Clinical Trial 4
  • Table 136: Endeavor Resolute Clinical Trial 5
  • Table 137: Endeavor Resolute Clinical Trial 6
  • Table 138: Endeavor Resolute Clinical Trial 7
  • Table 139: Endeavor Resolute Clinical Trial 8
  • Table 140: Endeavor Resolute Clinical Trial 9
  • Table 141: Endeavor Resolute Clinical Trial 10

List of Figures

  • Figure 1: Coronary Heart Disease, Signs and Symptoms
  • Figure 2: Drug Eluting Stents Market, Global, Revenue ($m), 2003-2010
  • Figure 3: Drug Eluting Stents Market, Global, Revenue ($m), 2010-2017
  • Figure 4: Drug Eluting Stents Market, Global, Volume (‘000), 2003-2010
  • Figure 5: Drug Eluting Stents Market, Global, Volume (‘000), 2010-2017
  • Figure 6: Drug Eluting Stents, Global, Market Dynamics
  • Figure 7: Coronary Heart Disease, the US, Prevalence (%), 2010-2030
  • Figure 8: Coronary Heart Disease in Men by Age, the UK, Prevalence (%), 2000-2008
  • Figure 9: Coronary Heart Disease in Women by Age, the UK, Prevalence (%), 2000-2008
  • Figure 10: Population Aged 65 and Above, Global, Population (million), 2004-2010
  • Figure 11: Population Aged 60 and Above, the US, Population (million) and Population Aged 60 and Above as a Percentage (%) of Adult Population, 2000-2050
  • Figure 12: Prevalence of Coronary Heart Disease in Population Aged between 60-79 and Population Aged 80 and Above, the US, Prevalence (%), 2006
  • Figure 13: Population Aged 65 and above, the UK, Population (million) and Population Aged 65 and Above as a Percentage (%) of Adult Population, 2000-2050
  • Figure 14: Coronary Heart Disease in Men Aged 65 and Above, the UK, Prevalence (%), 2000-2008
  • Figure 15: Coronary Heart Disease in Women Aged 65 and Above, the UK, Prevalence (%), 2000-2008
  • Figure 16: Tobacco Consumption, Global, Population (billion), 2000-2050
  • Figure 17: Percutaneous Coronary Intervention Procedure (million), Global, 2003-2010
  • Figure 18: Percutaneous Coronary Intervention Procedure (million), the US, 2003-2010
  • Figure 19: Percutaneous Coronary Intervention Procedure (‘000), Europe, 2003-2010
  • Figure 20: Drug Eluting Stents, the US and the UK, Average Selling Price ($), 2003-2010
  • Figure 21: Drug Eluting Stents Market, the US, Revenue ($bn), 2003-2010
  • Figure 22: Drug Eluting Stents Market, the US, Volume (million), 2003-2010
  • Figure 23: Drug Eluting Stents Market, the US, Revenue ($bn), 2010-2017
  • Figure 24: Drug Eluting Stents Market, the US, Volume (million), 2010-2017
  • Figure 25: Drug Eluting Stents Market, Canada, Revenue ($m), 2003-2010
  • Figure 26: Drug Eluting Stents Market, Canada, Volume (‘000), 2003-2010
  • Figure 27: Drug Eluting Stents Market, Canada, Revenue ($m), 2010-2017
  • Figure 28: Drug Eluting Stents Market, Canada, Volume (‘000), 2010-2017
  • Figure 29: Drug Eluting Stents Market, the UK, Revenue ($m), 2003-2010
  • Figure 30: Drug Eluting Stents Market, the UK, Volume (‘000), 2003-2010
  • Figure 31: Drug Eluting Stents Market, the UK, Revenue ($m), 2010-2017
  • Figure 32: Drug Eluting Stents Market, the UK, Volume (‘000), 2010-2017
  • Figure 33: Drug Eluting Stents Market, Germany, Revenue ($m), 2003-2010
  • Figure 34: Drug Eluting Stents Market, Germany, Volume (‘000), 2003-2010
  • Figure 35: Drug Eluting Stents Market, Germany, Revenue ($m), 2010-2017
  • Figure 36: Drug Eluting Stents Market, Germany, Volume (‘000), 2010-2017
  • Figure 37: Drug Eluting Stents Market, France, Revenue ($m), 2003-2010
  • Figure 38: Drug Eluting Stents Market, France, Volume (‘000), 2003-2010
  • Figure 39: Drug Eluting Stents Market, France, Revenue ($m), 2010-2017
  • Figure 40: Drug Eluting Stents Market, France, Volume (‘000), 2010-2017
  • Figure 41: Drug Eluting Stents Market, Italy, Revenue ($m), 2003-2010
  • Figure 42: Drug Eluting Stents Market, Italy, Volume (‘000), 2003-2010
  • Figure 43: Drug Eluting Stents Market, Italy, Revenue ($m), 2010-2017
  • Figure 44: Drug Eluting Stents Market, Italy, Volume (‘000), 2010-2017
  • Figure 45: Drug Eluting Stents Market, Spain, Revenue ($m), 2003-2010
  • Figure 46: Drug Eluting Stents Market, Spain, Volume (‘000), 2003-2010
  • Figure 47: Drug Eluting Stents Market, Spain, Revenue ($m), 2010-2017
  • Figure 48: Drug Eluting Stents Market, Spain, Volume (‘000), 2010-2017
  • Figure 49: Drug Eluting Stents Market, Japan, Revenue ($m), 2003-2010
  • Figure 50: Drug Eluting Stents Market, Japan, Volume (‘000), 2003-2010
  • Figure 51: Drug Eluting Stents Market, Japan, Revenue ($m), 2010-2017
  • Figure 52: Drug Eluting Stents Market, Japan, Volume (‘000), 2010-2017
  • Figure 53: Drug Eluting Stents Market, China, Revenue ($m), 2003-2010
  • Figure 54: Drug Eluting Stents Market, China, Volume (‘000), 2003-2010
  • Figure 55: Drug Eluting Stents Market, China, Revenue ($m), 2010-2017
  • Figure 56: Drug Eluting Stents Market, China, Volume (‘000), 2010-2017
  • Figure 57: Drug Eluting Stents Market, India, Revenue ($m), 2003-2010
  • Figure 58: Drug Eluting Stents Market, India, Volume (‘000), 2003-2010
  • Figure 59: Drug Eluting Stents Market, India, Revenue ($m), 2010-2017
  • Figure 60: Drug Eluting Stents Market, India, Volume (‘000), 2010-2017
  • Figure 61: Drug Eluting Stents Market, Australia, Revenue ($m), 2003-2010
  • Figure 62: Drug Eluting Stents Market, Australia, Volume (‘000), 2003-2010
  • Figure 63: Drug Eluting Stents Market, Australia, Revenue ($m), 2010-2017
  • Figure 64: Drug Eluting Stents Market, Australia, Volume (‘000), 2010-2017
  • Figure 65: Drug Eluting Stents Market, Brazil, Revenue ($m), 2003-2010
  • Figure 66: Drug Eluting Stents Market, Brazil, Volume (‘000), 2003-2010
  • Figure 67: Drug Eluting Stents Market, Brazil, Revenue ($m), 2010-2017
  • Figure 68: Drug Eluting Stents Market, Brazil, Volume (‘000), 2010-2017
  • Figure 69: Drug Eluting Stents Market, Global, Company Share (%), 2010
  • Figure 70: Boston Scientific Corporation, SWOT Analysis
  • Figure 71: Abbott Laboratories, SWOT Analysis
  • Figure 72: Medtronic Inc., SWOT Analysis
  • Figure 73: Cordis Corporation, SWOT Analysis
  • Figure 74: Drug Eluting Stents Market, Key Marketed Products
  • Figure 75: Pipeline Products, by Development Stage, 2011
  • Figure 76: Drug Eluting Stents, Deals Landscape, 2009-2010
Back to Top